Paris-Based Orakl Oncology Raises $34M Series A Co-Led by Norrsken VC and Singular to Predict Cancer Trial Outcomes With AI

The Gustave Roussy spin-out grows patients' tumors in the lab and uses AI to forecast how drugs will perform before human trials.

Orakl Oncology, a Paris-based TechBio company that uses lab-grown tumors and AI to predict how cancer drugs will perform in patients, has raised an oversubscribed $34 million Series A co-led by Norrsken VC and Singular, HIT Consultant reported on November 12, 2026. European outlets reported the round as €30 million. The raise brings Orakl's total funding to $50 million.


Who Invested


Swedish investor Norrsken VC and French firm Singular co-led the round. New investors InfraVia, Serena, Bpifrance's Patient Autonome Fund, teampact.ventures and Plug and Play joined, along with returning backers Verve Ventures, Speedinvest and HCVC.


Angel investors include Hugging Face co-founder Thomas Wolf, Stan Polu, Jacques Boitreaud and Mostafa El Sayed. Valuation was not disclosed.


What Orakl Oncology Does


Most cancer drugs that enter clinical trials never make it to patients. Orakl wants to know which ones will work before they reach patients.


The company builds cohorts of what it calls virtual cancer patients. It grows real patients' tumors as 3D organoids in the lab, tests drugs against them, adds multi-omic profiling and long-term clinical records, and feeds the results into machine learning models. The goal is causal evidence of how specific tumor subtypes respond to a compound before a human trial begins.


Orakl was founded in 2023 as a spin-out of the Gustave Roussy cancer campus. Dr. Fanny Jaulin is CEO and co-founder.


Traction


Just over a year after its commercial launch, Orakl says its pipeline spans 18 of the world's top 20 pharmaceutical companies, with early engagements turning into multi-year collaborations. It is evaluating oncology assets for Sanofi and has more than 10 active drug development programs.


The company claims 90% accuracy in predicting clinical trial outcomes, a figure that has not been independently verified. It is also negotiating with more than 15 additional cancer centers in Europe, North America and Asia to expand its data.


What the Money Is For


Orakl plans to expand its proprietary dataset and AI research team in Paris, increase lab data generation fivefold, move beyond colorectal and pancreatic cancers into non-small cell lung and gastric cancers, build commercial and scientific teams in the U.S. and U.K., and push into earlier-stage drug target discovery.


Why It Matters


Late-stage trial failures are among the most expensive setbacks in drug development. If Orakl's predictions hold up, pharma companies could kill weak drug candidates earlier and design trials around the patients most likely to respond. That promise helps explain why 18 of the top 20 drugmakers are already in its commercial pipeline.


The 90% accuracy claim is the number everything rides on. Validated multi-year deals with big pharma, rather than pilots, will be the clearest sign that the industry trusts it.


Source


HIT Consultant — "Orakl Oncology Raises $34M to Predict Cancer Clinical Trial Outcomes with 90% Accuracy"

0 Comments